Neural Therapeutics Receives Conditional Approval for Listing on CSE

Neural Therapeutics Inc. has announced that it has obtained conditional approval from the Canadian Securities Exchange (CSE) for the listing of its shares. This milestone follows a previously disclosed fundamental change transaction that involves CWE European. The approval from the CSE is a significant step for Neural Therapeutics, as it aims to strengthen its position in the Canadian market. The company is focused on advancing its business strategies in the therapeutic sector, leveraging this new approval to attract potential investors and expand its operations. The listing is expected to provide additional resources and visibility for Neural Therapeutics as it navigates its growth trajectory.